SHINE Technologies Partners with Blue Earth Therapeutics for First Supply of Ilumira from Its New Facility

Blue Earth Therapeutics will leverage SHINE's non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for prostate cancer undergoing clinical trials

JANESVILLE, Wis., June 6, 2024 /PRNewswire/ -- SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals. SHINE has provided the first supply of Ilumira – its non-carrier added lutetium-177 (n.c.a. Lu-177) chloride – to Blue Earth Therapeutics that will be used in clinical trials to assess a potential treatment for men with prostate cancer. This partnership follows SHINE's submission of a Drug Master File to the U.S. Food and Drug Administration – enabling SHINE to be on a fast track to deliver for its customers.

Preview

来源: PRNewswire

Ilumira

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。